Immunoglobulin Patents (Class 536/23.53)
-
Patent number: 8945571Abstract: The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: GrantFiled: August 17, 2010Date of Patent: February 3, 2015Assignee: Roche GlyeArt AGInventors: Ekkehard Mössner, Ralf Jörg Hosse, Pablo Umaña, Michela Silacci-Melkko
-
Publication number: 20150030602Abstract: A novel monoclonal antibody and like antigen-binding molecules against transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFE2) are provided with unique immunological and biological properties useful in the therapy of affective disorders such as depression and bipolar disorders as well as anxiety disorders. In addition, pharmaceutical compositions and kits comprising such antibody and derivatives thereof are described.Type: ApplicationFiled: January 2, 2013Publication date: January 29, 2015Applicant: PHENOQUEST AGInventors: Ingeborg Sillaber, Marcelo Paez-Pereda
-
Publication number: 20150030598Abstract: The present invention relates to tri- or tetraspecific antibodies, their manufacture and use.Type: ApplicationFiled: June 25, 2014Publication date: January 29, 2015Inventors: Rebecca CROASDALE, Christian KLEIN, Wolfgang SCHAEFER, Juergen Michael SCHANZER
-
Publication number: 20150030606Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.Type: ApplicationFiled: October 7, 2014Publication date: January 29, 2015Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
-
Publication number: 20150030600Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: ApplicationFiled: August 31, 2011Publication date: January 29, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
-
Publication number: 20150031870Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.Type: ApplicationFiled: September 16, 2014Publication date: January 29, 2015Inventors: SIMON MARK JACKSON, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
-
Publication number: 20150030592Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: ApplicationFiled: August 12, 2014Publication date: January 29, 2015Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Patent number: 8940963Abstract: Process of producing in a plant, in plant tissue, or in plant cells a hetero-oligomeric protein comprising at least a first and a second protein subunit, said process comprising expressing in plant cells at least said first and said second protein subunit by (i) providing to said plant, said plant tissue or said plant cells a plus-sense single-stranded RNA viral vector encoding at least said first and said second protein subunit or (ii) providing to said plant, said plant tissue or said plant cells a first and a second plus-sense single-stranded RNA viral vector, said first viral vector encoding at least said first protein subunit, said second viral vector encoding at least said second protein subunit, whereby at least said first viral vector and said second viral vector are non-competing viral vectors.Type: GrantFiled: January 27, 2006Date of Patent: January 27, 2015Assignee: Icon Genetics GmbHInventors: Anatoly Giritch, Sylvestre Marillonnet, Victor Klimyuk, Yuri Gleba
-
Patent number: 8940883Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: January 31, 2013Date of Patent: January 27, 2015Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Patent number: 8940276Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 21, 2009Date of Patent: January 27, 2015Assignees: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20150025228Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Youb JUNG, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20150023956Abstract: Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibodies provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis III (MPS-III). The fusion antibodies provided herein comprise N-sulfoglucosamine sulfohydrolase (SGSH), alpha-N-acetylgulcosaminidase (NAGLU), heparin-alpha-glucosaminide N-acetyltransferase (HGSNAT), or N-acetylglucosamine-6-sulfatase (GNS). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein.Type: ApplicationFiled: May 19, 2014Publication date: January 22, 2015Applicant: ArmaGen Technologies, Inc.Inventors: William M. PARDRIDGE, Ruben J. BOADO
-
Publication number: 20150023871Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: September 29, 2014Publication date: January 22, 2015Applicant: GENENTECH, INC.Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
-
Publication number: 20150023966Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: ApplicationFiled: November 6, 2012Publication date: January 22, 2015Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, SAndrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainney, Cuihua GAO
-
Publication number: 20150024433Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: ApplicationFiled: July 24, 2014Publication date: January 22, 2015Applicant: NEOTOPE BIOSCIENCES LIMITEDInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Publication number: 20150023976Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: ApplicationFiled: October 9, 2014Publication date: January 22, 2015Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
-
Publication number: 20150023957Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventors: Haichao Wang, Andrew E. Sama, Wei Li, Kevin J. Tracey
-
Publication number: 20150023978Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: January 17, 2014Publication date: January 22, 2015Applicants: Baxter International Inc., Dyax Corp., Baxter Healthcare SAInventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Publication number: 20150024482Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.Type: ApplicationFiled: February 22, 2013Publication date: January 22, 2015Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
-
Publication number: 20150023999Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.Type: ApplicationFiled: November 29, 2012Publication date: January 22, 2015Inventors: Simon Urwyler, Markus Haake, Michael Rodolf
-
Publication number: 20150025227Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Youb JUNG, Jin Sun Kim, Geun Hee Yang, Se Wang Kwon, Gwan Sun Lee
-
Publication number: 20150023967Abstract: The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: ApplicationFiled: November 15, 2012Publication date: January 22, 2015Inventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Publication number: 20150017178Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.Type: ApplicationFiled: February 19, 2014Publication date: January 15, 2015Inventor: Antonio Francesco DI NARO
-
Publication number: 20150018529Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.Type: ApplicationFiled: February 22, 2013Publication date: January 15, 2015Inventors: David Paul Humphreys, Shirley Jane Peters
-
Publication number: 20150018532Abstract: The invention relates to antibodies to Aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the Aspergillus species and to methods of treating an infection with the Aspergillus species.Type: ApplicationFiled: June 6, 2014Publication date: January 15, 2015Applicant: UNIVERSITY OF EXETERInventor: Christopher THORNTON
-
Publication number: 20150017127Abstract: Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.Type: ApplicationFiled: September 12, 2014Publication date: January 15, 2015Inventors: Clodagh O'Shea, Shigeki Miyake-Stoner, Colin Powers
-
Publication number: 20150017154Abstract: A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or nucleic acids.Type: ApplicationFiled: May 8, 2012Publication date: January 15, 2015Inventor: David Gearing
-
Publication number: 20150017172Abstract: This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient.Type: ApplicationFiled: February 21, 2013Publication date: January 15, 2015Applicant: Toray Industries, Inc.Inventors: Shinichi Kobayashi, Fumiyoshi Okano, Takanori Saito
-
Publication number: 20150018531Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.Type: ApplicationFiled: February 22, 2013Publication date: January 15, 2015Applicant: STEM CENTRX, INC.Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
-
Publication number: 20150017095Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Inventors: Tariq Ghayur, Jijie Gu, Peter Isakson
-
Publication number: 20150017167Abstract: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: ApplicationFiled: September 18, 2014Publication date: January 15, 2015Inventors: Naoki NISHIGUCHI, Akiyoshi HIRAYAMA, Masahiro FURUTANI, Tatsuo SHIMIZU, Kiyoshi TAKAYAMA, Tomoko SHIMIZU, Kazuya SUZUKI
-
Publication number: 20150017171Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.Type: ApplicationFiled: July 21, 2014Publication date: January 15, 2015Inventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20150017183Abstract: Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described.Type: ApplicationFiled: December 20, 2012Publication date: January 15, 2015Inventors: Nabil G. Seidah, Jianbing Zhang
-
Publication number: 20150018408Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.Type: ApplicationFiled: July 10, 2014Publication date: January 15, 2015Inventors: Nicholas W. Lukacs, Steven L. Kunkel, Cory Hogaboam
-
Patent number: 8932592Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: GrantFiled: October 28, 2010Date of Patent: January 13, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Publication number: 20150010946Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: ApplicationFiled: June 5, 2014Publication date: January 8, 2015Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
-
Publication number: 20150010998Abstract: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: ApplicationFiled: September 18, 2014Publication date: January 8, 2015Inventors: Naoki NISHIGUCHI, Akiyoshi HIRAYAMA, Masahiro FURUTANI, Tatsuo SHIMIZU, Kiyoshi TAKAYAMA, Tomoko SHIMIZU, Kazuya SUZUKI
-
Publication number: 20150011431Abstract: The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 (e.g. bovine) and uses thereof.Type: ApplicationFiled: January 9, 2013Publication date: January 8, 2015Inventors: Vaughn Smider, Omar A. Bazirgan, Hongyuan Helen Mao
-
Publication number: 20150010546Abstract: The present invention relates to biological materials against HGF and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit binding of HGF to its receptor c-Met.Type: ApplicationFiled: January 16, 2013Publication date: January 8, 2015Inventors: Joost Alexander Kolkman, Hilde Adi Pierrette Revets, Jo Vercammen, Augustinus Antonius Maria Silvester van Dongen
-
Publication number: 20150010543Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: ApplicationFiled: July 8, 2014Publication date: January 8, 2015Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Publication number: 20150010560Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.Type: ApplicationFiled: June 13, 2014Publication date: January 8, 2015Inventors: Cen XU, Agnes Eva HAMBURGER
-
Publication number: 20150010547Abstract: Recombinant antibodies (including binding fragments thereof) that bind IgE are described, along with compositions and methods of using the same in the treatment of subjects in need thereof, including subjects afflicted with atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, gastro-intestinal inflammation, or oral-pharyngeal inflammation. In some embodiments, the antibody is a single chain variable fragment (scFv) or a disulfide linked variable fragment (sdFv). In some embodiments, the subject is a dog, cat, or horse.Type: ApplicationFiled: January 29, 2013Publication date: January 8, 2015Inventor: Bruce Hammerberg
-
Publication number: 20150010539Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.Type: ApplicationFiled: March 14, 2014Publication date: January 8, 2015Applicant: AbbVie Biotherapeutics Inc.Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING, PAUL R. HINTON, MENGLI XIONG, OLIVIA JENNIFER RAZO, SHIMING YE
-
Publication number: 20150010538Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.Type: ApplicationFiled: March 14, 2014Publication date: January 8, 2015Applicant: AbbVie Biotherapeutics Inc.Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING
-
Publication number: 20150010574Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.Type: ApplicationFiled: June 13, 2014Publication date: January 8, 2015Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Paul ADAM, Eric BORGES
-
Publication number: 20150010542Abstract: The present invention provides methods and compositions for modulating Toso activity and treating diseases and disorders in which Toso is implicated. Such methods and compositions include the use of one or more antibodies that bind to a Toso protein or to a ligand of a Toso protein.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Inventors: Tak W. Mak, Xiuqiu Lai, Michael W. Tusche
-
Publication number: 20150010566Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.Type: ApplicationFiled: December 3, 2012Publication date: January 8, 2015Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
-
Patent number: 8926971Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: June 20, 2012Date of Patent: January 6, 2015Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20150004173Abstract: A peptide is disclosed of the general structure: Z—W—Y, wherein Z and Y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and W is a non-hydrolyzable pHis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies. Also provided are antibodies that specifically bind to a peptide comprising a phosphohistidine (or a non-hydrolyzable pHis analogue) but fail to specifically bind to an identical peptide containing histidine instead of phosphohistidine.Type: ApplicationFiled: September 12, 2014Publication date: January 1, 2015Inventors: Magda Stankova, Fahad Al-Obeidi, Jacques Mauger, Robert A. Binnie, Tony Hunter, Jill Meisenhelder, Stephen Rush Fuhs
-
Publication number: 20150004171Abstract: This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancers. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancers, comprising the antibody or fragment thereof as an active ingredient.Type: ApplicationFiled: February 21, 2013Publication date: January 1, 2015Applicant: TORAY INDUSTRIES, INC.Inventors: Shinichi Kobayashi, Fumiyoshi Okano, Takanori Saito